Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 118

Results For "EY"

3103 News Found

Evonik showcases smart technology for dental prostheses
News | July 05, 2023

Evonik showcases smart technology for dental prostheses

PEEK brings a new quality to dental care for patients


Biocon Biologics expands footprint in emerging markets
News | July 05, 2023

Biocon Biologics expands footprint in emerging markets

Takes over the commercialization of Biosimilars Business from Viatris in 70+ countries


Healthium Medtech appoints Dr. Vivek S. Iyer as GM for Professional Education & Market Growth Strategy
People | July 05, 2023

Healthium Medtech appoints Dr. Vivek S. Iyer as GM for Professional Education & Market Growth Strategy

Dr. Vivek joins Healthium after a stint at Ethicon, Johnson & Johnson


Biocon Biologics' Hulio Biosimilar to Humira now available in the US
News | July 04, 2023

Biocon Biologics' Hulio Biosimilar to Humira now available in the US

The launch of HULIO in the United States is an important milestone for Biocon Biologics


Adare Pharma divests Adare Biome to dsm-firmenich
News | July 04, 2023

Adare Pharma divests Adare Biome to dsm-firmenich

The transaction represents an enterprise value of €275 million, an estimated 2023 EV/EBITDA multiple of 18x


Anupam Rasayan signs MoU with 3xper Innoventure for new age pharma molecules
News | July 04, 2023

Anupam Rasayan signs MoU with 3xper Innoventure for new age pharma molecules

The identified products for Active Pharmaceutical Ingredients (API) will be developed under the CRAMS and CDMO models


Annovis’ Buntanetap in PD faces complex road ahead despite phase III progress, says GlobalData
News | July 03, 2023

Annovis’ Buntanetap in PD faces complex road ahead despite phase III progress, says GlobalData

The positive safety review from the DSMB enables the trial to move forward as planned, with an estimated completion date in December 2023


Sanofi reaffirms ambition to deliver >€10bn in annual vaccines sales by 2030
News | July 03, 2023

Sanofi reaffirms ambition to deliver >€10bn in annual vaccines sales by 2030

Intent to start at least 5 innovative Phase 3 vaccine programs by 2025


Lupin achieves milestone for its phase 1 clinical stage MALT1 inhibitor program
News | June 30, 2023

Lupin achieves milestone for its phase 1 clinical stage MALT1 inhibitor program

Lupin has received US$ 25 million from AbbVie for initiation of Phase 1 clinical studies successfully


Rystiggo needs marketing strategy to fully compete in myasthenia gravis space, says GlobalData
News | June 30, 2023

Rystiggo needs marketing strategy to fully compete in myasthenia gravis space, says GlobalData

Decisions on the marketing authorization for Rystiggo in the European and Japanese markets are expected in Q1 of 2024